Key clinical point: Brain-responsive stimulation reduced seizure frequency and could assist patient management.
Major finding: Seizure reduction was 84% after 3 years in the real-world analysis and 75% in the extension study.
Study details: Retrospective real-world analysis (n = 150) and prospective extension study (n = 230).
Disclosures: The extension study was funded by NeuroPace. NeuroPace supported data entry and institutional review board submission for the real-world trial. Some study investigators reported owning stock in, being an employee of, receiving support from, and/or consulting for NeuroPace.